ARADIGM CORP. ARDM Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARADIGM CORP. ARDM

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (136)	5/10/2002 8:18:27 AM
From: rkrw	Read Replies (3) of 255

<<<Has ARDM given an indication of how much more their inhaler costs?>>> I'm not sure. The opposite is alks with a very low cost inhaler. <<<I gather including a microprocessor adds some cost, and while it may not be worth it for Flovent, maybe it is for other things? Now that the fibrosis issues have arisen from inhaling proteins, I can see why. Can you think of any such molecules that would benefit from precision pulmonary delivery (outside of the pain program)? Should they be talking to SEPR?>>> Insulin :-) actually fibrosis hasn't yet been seen with ardm's aerx but that doesn't mean it won't. ardm's device imo would be most applicable to expensive drugs for serious conditions, something like itmn's Actimmune. They had a deal for dna's pulmozyme which would have been a good fit, but dna decided an incremental improvement in delivery wasn't worth the investment. Sepr has already gone with 3M for xopenex mdi's. I don't think it would have been wise for sepr to go with ardm.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next